HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission

Current HIV Research

Volumn 11, Issue 2, 2013, Pages 126-136

  Ton, Quy ^a   Frenkel, Lisa ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

HIV; HIV drug resistance; Nevirapine; Prevention of mother to child transmission of HIV; Zidovudine

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POINT MUTATION; PREVALENCE; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; APTAMERS, NUCLEOTIDE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOTHERS; NEVIRAPINE; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; ZIDOVUDINE;

EID: 84875830325     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X11311020005     Document Type: Review

References (125)

1. World-Health-Organization. Prevention of mother-to-child transmission of HIV: Selection and use of nevirapine. Technical notes. Geneva 2001.
2. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15(15): 1951-7.
3. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192(1): 24-9.
4. Eshleman SH, Guay LA, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 2005; 40(1): 24-9.
5. Eshleman SH, Hoover DR, Chen S, et al. Resistance after singledose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19(18): 2167-9.
6. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192(1): 30-6.
7. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42(5): 610-3.
8. Eshleman SH, Hoover DR, Hudelson SE, et al. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis 2006; 193(4): 479-81.
9. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapineresistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006; 103(18): 7094-9.
10. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103Ncontaining HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195(5): 711-5.
11. Dross S, Beck IA, Micek MA, et al. Transmission of NVP-resistant HIV-1 to infants by breastfeeding observed after maternal sdNVP. 17th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada 2010.
12. Micek MA, Blanco AJ, Beck IA, et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis 2010; 50(10): 1405-14.
13. Farr SL, Nelson JA, Ng'ombe TJ, et al. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIVinfected mothers in Malawi. J Acquir Immune Defic Syndr 2010; 54(5): 515-23.
14. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351(3): 229-40.
15. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356(2): 135-47.
16. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010; 304(10): 1082-90.
17. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363(16): 1499-509.
18. Jourdain G, Wagner TA, Ngo-Giang-Huong N, et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis 2010; 50(10): 1397-404.
19. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363(16): 1510-20.
20. Moorthy A, Kuhn L, Coovadia A, et al. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis 2011; 52(4): 514-21.
21. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192(1): 16-23.
22. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20(7): 995-1002.
23. Flys TS, Mwatha A, Guay LA, et al. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. AIDS 2007; 21(15): 2077-82.
24. World-Health-Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, Geneva 2010.
25. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One 2009; 4(1): e4096.
26. Fogel J, Hoover DR, Sun J, et al. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS 2011; 25(7): 911-7.
27. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8(3): e1000430.
28. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52(8): 1069-76.
29. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004; 38(5): 723-30.
30. Meynard JL, Vray M, Morand-Joubert L, et al. Impact of Treatment guided by Phenotypic or Genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antivir Ther 2003; 8(5): 427-34.
31. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16(5): 727-36.
32. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47(2): 266-85.
33. Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002; 18(4): 243-8.
34. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344(7): 472-80.
35. Halvas EK, Aldrovandi GM, Balfe P, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006; 44(7): 2612-4.
36. Shi C, Eshleman SH, Jones D, et al. LigAmp for sensitive detection of single-nucleotide differences. Nature Methods 2004; 1(2): 141-7.
37. Frenkel LM, Wagner LE, 2nd, Atwood SM, Cummins TJ, Dewhurst S. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol 1995; 33(2): 342-7.
38. Johnson J, Li JF, Wei X, et al. Low-frequency mutations substantially increase the prevalence of transmitted drug resistance and greatly strengthen the relationship between resistance mutations and virologic failure. 14th Conference on Human Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA 2007.
39. Beck I, Deng W, Hall R, et al. Quantification and dynamics of HIV-1 drug resistant mutants in women and infants exposed to maternal zidovudine and single-dose NVP by pyrosequencing and oligonucleotide ligation assay. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Rome, Italy 2011.
40. Beck IA, Crowell C, Kittoe R, et al. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr 2008; 48(4): 418-27.
41. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305(13): 1327-35.
42. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351(3): 217-28.
43. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci USA 2011; 108(22): 9202-7.
44. Rowley CF, Boutwell CL, Lee EJ, et al. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses 2010; 26(3): 293-300.
45. Wagner TA, Kress CM, Beck I, et al. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol 2010; 48(5): 1555-61.
46. Ellis GM, Marushchak T, Koth A, et al. Simultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay. J Virol Methods. In press.
47. Johnson VA, Calvez V, Gunthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19(4): 156-64.
48. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68(3): 1660-6.
49. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 2001; 29(1): 296-9.
50. Boucher CA, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105-10.
51. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-9.
52. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362(24): 2282-94.
53. World-Health-Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Geneva 2006.
54. Wagner TA, Kress CM, Beck I, et al. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol 2010; 48(5): 1555-61.
55. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282(12): 1142-9.
56. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82(11): 5510-8.
57. Schacker T, Little S, Connick E, et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis 2000; 181(1): 354-7.
58. Price MA, Wallis CL, Lakhi S, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011; 27(1): 5-12.
59. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 Suppl 2: 1-13.
60. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2: 25-36.
61. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13 Suppl 2: 15-23.
62. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008; 13 Suppl 2: 95-100.
63. Myatt M, Bennett DE. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by crosssectional survey for use in low resource settings. Antivir Ther 2008; 13 Suppl 2: 37-48.
64. Nguyen HT, Duc NB, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 2008; 13 Suppl 2: 115-21.
65. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 Suppl 2: 101-7.
66. Shafer RW, Rhee SY, Bennett DE. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther 2008; 13 Suppl 2: 59-68.
67. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13 Suppl 2: 77-82.
68. Connor EM, Mofenson LM. Zidovudine for the reduction of perinatal human immunodeficiency virus transmission: pediatric AIDS Clinical Trials Group Protocol 076--results and treatment recommendations. Pediatr Infect Dis J 1995; 14(6): 536-41.
69. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177(3): 557-64.
70. Frenkel LM, McKernan J, Dinh PV, et al. HIV type 1 zidovudine (ZDV) resistance in blood and uterine cervical secretions of pregnant women. AIDS Res Hum Retroviruses 2006; 22(9): 870-3.
71. Frenkel LM, Wagner LE 2nd, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 1995; 20(5): 1321-6.
72. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 20(9): 1281-8.
73. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335(15): 1081-90.
74. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29(5): 484-94.
75. Lindegren ML, Byers RH Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999; 282(6): 531-8.
76. World-Health-Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: Progress report. Geneva 2009.
77. Ellis GM, Huang S, Hitti J, Frenkel LM. Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. J Acquir Immune Defic Syndr 2011; 58(3): 241-7.
78. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362(9387): 859-68.
79. Stringer EM, Ekouevi DK, Coetzee D, et al. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA 2010; 304(3): 293-302.
80. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36(5): 1009-21.
81. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of motherto-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. J Acquir Immune Defic Syndr 2005; 39(5): 593-7.
82. Lockman S. Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy. Curr Opin HIV AIDS. 2008; 3(2):166-72.
83. Lockman S, McIntyre JA. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. Lancet 2007; 370(9600): 1668-70.
84. Martinson NA, Ekouevi DK, Dabis F, et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2007; 45(2): 206-9.
85. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193(4): 482-7.
86. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6(10): e1000172.
87. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370(9600): 1698-705.
88. Chi BH, Ellis GM, Chintu N, et al. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention. AIDS Res Hum Retroviruses 2009; 25(11): 1099-106.
89. Arrive E, Chaix ML, Nerrienet E, et al. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 2009; 23(7): 825-33.
90. Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29(2): 306-9.
91. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28(5): 1032-5.
92. Lallemant M, Jourdain G. Preventing mother-to-child transmission of HIV-protecting this generation and the next. N Engl J Med 2010; 363(16): 1570-2.
93. Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, et al. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. Clin Infect Dis 2012; 54(2): 285-93.
94. Martinson NA, Morris L, Gray G, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007; 44(2): 148-53.
95. McConnell M, Bakaki P, Eure C, et al. Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. J Acquir Immune Defic Syndr 2007; 46(3): 291-6.
96. Walter J, Kuhn L, Kankasa C, et al. Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of motherto-child HIV transmission in Lusaka, Zambia: a cohort study. BMC Infect Dis 2008; 8: 172.
97. Martinson NA, Morris L, Johnson J, et al. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS 2009; 23(7): 809-16.
98. Kuhn L, Sinkala M, Kankasa MP, Kasonde P, Thea DM, Aldrovandi GM. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission. J Acquir Immune Defic Syndr 2006; 42(2): 260-2.
99. Flys TS, McConnell MS, Matovu F, et al. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis 2008; 198(4): 465-9.
100. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitorbased therapy. Clin Infect Dis 2009; 48(4): 462-72.
101. Kuhn L, Semrau K, Ramachandran S, et al. Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr 2009; 52(1): 132-6.
102. Stringer JS, McConnell MS, Kiarie J, et al. Effectiveness of nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med 2010; 7(2): e1000233.
103. MacLeod IJ, Rowley CF, Thior I, et al. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol 2010; 48(3): 162-7.
104. Group KBS. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. J Acquir Immune Defic Syndr 2010; 54(5): 533-41.
105. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11(3): 171-80.
106. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283(9): 1167-74.
107. Arvelo W, Kim A, Creek T, et al. Case-control study to determine risk factors for diarrhea among children during a large outbreak in a country with a high prevalence of HIV infection. Int J Infect Dis 2010; 14(11): e1002-7.
108. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after singledose administration. J Antimicrob Chemother 2009; 63(1): 170-7.
109. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362(24): 2271-81.
110. Petra-Study-Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359: 1178-86.
111. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-35.
112. SWEN-Study-Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372: 300-13.
113. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359(2): 119-29.
114. Coovadia H, Brown E, Maldonado Y, et al. HPTN 046: efficacy of extended daily infant NVP through age 6 months compared to 6 weeks for postnatal PMTCT of HIV through breastfeeding. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA 2011.
115. Lidstrom J, Li Q, Hoover DR, et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 2010; 24(3): 381-6.
116. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53(3): 1170-6.
117. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36(3): 772-6.
118. Becquet R, Bland R, Ekouevi DK, Dabis F, Newell ML. Universal antiretroviral therapy among pregnant and postpartum HIVinfected women would improve maternal health and decrease postnatal HIV transmission. AIDS 2010; 24(8): 1239-41.
119. Ammann AJ. Optimal versus suboptimal treatment for HIVinfected pregnant women and HIV-exposed infants in clinical research studies. J Acquir Immune Defic Syndr 2009; 51(5): 509-12.
120. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001; 7(9): 1016-20.
121. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A costeffectiveness analysis. Clin Infect Dis 2005; 41(9): 1316-23.
122. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6): 493-505.
123. Geretti AM. Epidemiology of antiretroviral drug resistance in drugnaive persons. Curr Opin Infect Dis 2007; 20(1): 22-32.
124. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006; 41(4): 439-46.
125. World-Health-Organization. PMTCT strategic vision 2010-2015: preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals. Geneva 2010.